Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.

Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J.

Am J Med. 1990 Nov;89(5):561-8.

PMID:
2146875
2.

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.

Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N.

Am J Med. 1990 Nov;89(5):554-60.

PMID:
2239975
3.

Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome.

Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, Lloyd A.

Am J Med. 1997 Jul;103(1):38-43.

PMID:
9236484
4.

Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial.

Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D.

Am J Med. 1993 Feb;94(2):197-203.

PMID:
8430715
5.

Immunological and psychological dysfunction in patients receiving immunotherapy for chronic fatigue syndrome.

Hickie I, Lloyd A, Wakefield D.

Aust N Z J Psychiatry. 1992 Jun;26(2):249-56.

PMID:
1642616
6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.

Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.

O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A.

Health Technol Assess. 2006 Oct;10(37):iii-iv, ix-x, 1-121.

8.

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome.

Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, Peterson PK.

J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):119-26.

PMID:
8568124
9.

A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.

Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR.

J Clin Psychiatry. 2000 Sep;61(9):643-8.

PMID:
11030484
10.
11.
12.

A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G.

QJM. 2006 Jul;99(7):461-8. Epub 2006 Jun 29.

PMID:
16809351
13.

Cell-mediated immune function and the outcome of chronic fatigue syndrome.

Wilson A, Hickie I, Lloyd A, Hadzi-Pavlovic D, Wakefield D.

Int J Immunopharmacol. 1995 Aug;17(8):691-4.

PMID:
8847164
14.

Immunological abnormalities in patients with chronic fatigue syndrome.

Tirelli U, Marotta G, Improta S, Pinto A.

Scand J Immunol. 1994 Dec;40(6):601-8.

PMID:
7997849
15.

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N.

Brain. 2001 Jan;124(Pt 1):145-53.

PMID:
11133794
16.
17.

Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation.

Peakman M, Deale A, Field R, Mahalingam M, Wessely S.

Clin Immunol Immunopathol. 1997 Jan;82(1):83-91.

PMID:
9000046
18.

A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.

Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, Stiehm R, Stocks J, Rosenberg L, Shames RS, Corn B, Shearer WT, Bacot B, DiMaio M, Tonetta S, Adelman DC.

Clin Immunol. 1999 May;91(2):126-33.

PMID:
10227804
19.

Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.

Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McGuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, Pavletic ZS.

Cytotherapy. 2003;5(6):542-52.

PMID:
14660050
20.

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.

Ann Rheum Dis. 2008 Nov;67(11):1541-4. doi: 10.1136/ard.2007.083865. Epub 2008 Feb 14.

PMID:
18276741

Supplemental Content

Support Center